/ICU
ICU Stock - SeaStar Medical Holding Corporation
Healthcare|BiotechnologyNASDAQ
$0.24-16.85%
$0.05 (-16.85%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.27
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ICU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.24 – $0.25
TARGET (TP)$0.28
STOP LOSS$0.23
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.00
52W High$3.07
52W Low$0.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $135,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $135,000 | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-17,842,000 | $-14,210,000 | $-11,609,000 | $-4,449,000 | $-6,453,000 |
| Net Income | $-24,830,000 | $-26,232,000 | $-12,190,000 | $-4,596,000 | $-3,276,000 |
| Net Margin | -18392.6% | N/A | N/A | N/A | N/A |
| EPS | $-6.63 | $-30.26 | $-23.38 | $-8.81 | $-0.01 |
Company Overview
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ICUBeat Rate
45%
Last 11 quarters
Avg Surprise
-918.7%
EPS vs Estimate
Beats / Misses
5/6
Last 12 quarters
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q2 24
-3553.8%
$-4.75vs$-0.13
Q2 24
-3066.7%
$-4.75vs$-0.15
Q3 24
+27.0%
$-1.03vs$-1.41
Q4 24
+2.7%
$-1.10vs$-1.13
Q1 25
-1.1%
$-0.90vs$-0.89
Q2 25
+15.4%
$-0.44vs$-0.52
Q3 25
+58.1%
$-0.18vs$-0.43
Q4 25
+13.3%
$-0.13vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.43 | $-0.18 | +58.1% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.52 | $-0.44 | +15.4% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.89 | $-0.90 | -1.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.13 | $-1.10 | +2.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-1.41 | $-1.03 | +27.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.15 | $-4.75 | -3066.7% | ✗ MISS |
Q2 2024 | Apr 16, 2024 | $-0.13 | $-4.75 | -3553.8% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.25 | $-3.00 | -1100.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.25 | $-6.25 | -2400.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-5.00 | $-10.00 | -100.0% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | — | $-58.32 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-3.72 | — | — |
Q3 2022 | Aug 16, 2022 | — | $-3.12 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-3.47 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.22 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.45 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-2.18 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.04 | — | — |
Latest News
SeaStar Medical Holding shares are trading lower after the company announced a 1-for-10 reverse stock split.
📉 NegativeBenzinga•Dec 19, 2025, 02:20 PM
SeaStar Medical Announces 1-For-10 Reverse Stock Split, Effective Jan. 2, 2026
➖ NeutralBenzinga•Dec 18, 2025, 09:26 PM
ICU stock has given up its prior gain. SeaStar Medical shares were trading higher after the FDA approved a reduction in the mandatory enrollment size of its SAVE surveillance registry evaluating Quelimmune safety in pediatric AKI.
➖ NeutralBenzinga•Dec 2, 2025, 02:26 PM
SeaStar Medical shares are trading higher after the FDA approved a reduction in the mandatory enrollment size of its SAVE surveillance registry evaluating Quelimmune safety in pediatric AKI.
📈 PositiveBenzinga•Dec 2, 2025, 01:28 PM
SeaStar Medical Announces FDA Approval Of Reduction In Mandatory Enrollment Size Of SAVE Surveillance Registry Evaluating QUELIMMUNE Safety In Pediatric AKI
📈 PositiveBenzinga•Dec 2, 2025, 01:27 PM
SeaStar Medical Appoints Michael Messinger CFO
➖ NeutralBenzinga•Nov 17, 2025, 01:45 PM
SeaStar Medical Holding shares are trading lower after the company reported worse-than-expected Q3 sales results.
📉 NegativeBenzinga•Nov 13, 2025, 09:18 PM
SeaStar Medical Holding Q3 EPS $(0.13) Beats $(0.15) Estimate, Sales $183.000K Miss $250.000K Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:06 PM
ICU stock has given up its prior gain. ICU Medical shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance above estimates.
➖ NeutralBenzinga•Nov 7, 2025, 01:50 PM
CORRECTION: ICU Medical Ticker Is 'ICUI'
➖ NeutralBenzinga•Nov 7, 2025, 11:56 AM•Also:
SeaStar Medical Announces That Independent DSMB Recommends Continuing NEUTRALIZE-AKI Pivotal Trial Of Its Selective Cytopheretic Device Therapy For Adult Patients With Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
📈 PositiveBenzinga•Sep 24, 2025, 08:25 PM
SeaStar Medical To Present Preliminary SAVE Surveillance Registry Data On QUELIMMUNE Therapy For Pediatric AKI And Sepsis At The 5th International Symposium On Acute Kidney Injury In Children
➖ NeutralBenzinga•Sep 23, 2025, 12:26 PM
SeaStar Medical Highlights $69,146 Cost Savings With QUELIMMUNE Therapy In Pediatric AKI, Published In Journal Of Medical Economics
📈 PositiveBenzinga•Sep 2, 2025, 12:23 PM
SeaStar Medical Announces It Has Terminated CFO David Green; Eric Schlorff Appointed Interim CFO
📉 NegativeBenzinga•Aug 19, 2025, 08:09 PM
SeaStar Medical announces positive Nasdaq listing determination
📈 PositiveSeeking Alpha•Jul 2, 2025, 08:34 PM
Frequently Asked Questions about ICU
What is ICU's current stock price?
SeaStar Medical Holding Corporation (ICU) is currently trading at $0.24 per share. The stock has moved -16.85% today.
What is the analyst price target for ICU?
No analyst price targets are currently available for this stock.
What sector is SeaStar Medical Holding Corporation in?
SeaStar Medical Holding Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ICU's market cap?
SeaStar Medical Holding Corporation has a market capitalization of $0.01 billion, making it a small-cap company.
Does ICU pay dividends?
No, SeaStar Medical Holding Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
AIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to ICU for comparison